Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Immune-checkpoint inhibitors (ICIs) have become one of the main strategies for advanced cancers. ICIs are associated with many immune side effects, called immune-related adverse events (irAEs). Since irAE has various variations, it is important to carefully examine each individual case that develops irAE. We experienced a case of polymyalgia rheumatica (PMR)-like irAE after three courses of administration of Ipilimumab and Nivolumab for stage IV lung adenocarcinoma. We also confirmed that the activity of this irAE was detectable on the PET-CT scan performed to assess lung cancer progression. Given the limited reports of PMR-like irAE occurring after treatment with two immune checkpoint inhibitors, we present this case along with a review of the literature.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12197867 | PMC |
| http://dx.doi.org/10.1002/rcr2.70242 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sonographic Signatures of Immune Checkpoint Inhibitor-Associated Musculoskeletal Adverse Events.
Cancers (Basel)
July 2025
Division of Rheumatology, University of Washington, Seattle, WA 98195, USA.
: Immune checkpoint inhibitors (ICIs) transformed cancer treatment, producing significant survival benefits. However, ICIs can trigger toxicities called immune-related adverse events (irAEs), including inflammatory arthritis (IA) and polymyalgia rheumatica (PMR)-like syndromes. Our study aimed to systematically further characterize musculoskeletal ultrasound (MSKUS) findings in patients with ICI-IA and ICI-PMR, collectively referred to as "MSK-irAEs", and explore the role of US in guiding treatment.
View Article and Find Full Text PDFA Case of PMR-Like irAE Developing After Treatment With Ipilimumab and Nivolumab for Lung Cancer.
Respirol Case Rep
June 2025
Division of Pulmonary Medicine, Department of Internal Medicine Keio University School of Medicine Tokyo Japan.
Immune-checkpoint inhibitors (ICIs) have become one of the main strategies for advanced cancers. ICIs are associated with many immune side effects, called immune-related adverse events (irAEs). Since irAE has various variations, it is important to carefully examine each individual case that develops irAE.
View Article and Find Full Text PDFImaging Findings in Patients with Immune Checkpoint Inhibitor-Induced Arthritis.
Diagnostics (Basel)
August 2022
Department of Rheumatology, Hospital Clinic of Barcelona, 08036 Barcelona, Spain.
Unlabelled: Immune checkpoint inhibitor (ICI)-induced arthritis is an increasingly recognized adverse event in patients with oncologic disease during immunotherapy. Four patterns are well described, including rheumatoid arthritis (RA)-like, polymyalgia rheumatica (PMR)-like, psoriatic arthritis (PsA)-like, and oligo-monoarthritis, among others. Despite better clinical recognition of these syndromes, information about the main imaging findings is limited.
View Article and Find Full Text PDFPolymyalgia rheumatica-like syndrome from checkpoint inhibitor therapy: case series and systematic review of the literature.
RMD Open
April 2020
Rheumatic & Immunologic Disease, Cleveland Clinic, Cleveland, Ohio, USA.
Objective: To assess whether the polymyalgia rheumatica (PMR)-like syndrome reported as an immune related adverse event (irAE) from checkpoint inhibitor therapy is consistent with the 2012 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) provisional criteria for PMR.
Methods: The cases were derived from two sources. Group 1 represents reported cases from three contributing centres.